

SCHERING PLOUGH CORP

Form 8-K

November 26, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): November 19, 2007  
SCHERING PLOUGH CORPORATION  
(Exact Name of Registrant as Specified in its Charter)**

New Jersey (State or Other Jurisdiction of Incorporation)	1-6571 (Commission File Number)	22-1918501 (IRS Employer Identification Number)
2000 Galloping Hill Road Kenilworth, NJ 07033 (Address of Principal Executive Office)		
Registrant's telephone number, including area code: (908) 298-4000		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 2.01 COMPLETION OF ACQUISITION OF ASSETS.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

SIGNATURES

Exhibit Index

EX-99.1: PRESS RELEASE

---

**Table of Contents**

ITEM 2.01 COMPLETION OF ACQUISITION OF ASSETS.

On November 19, 2007, Schering-Plough Corporation closed the acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. for approximately \$1 billion in cash. Organon BioSciences is comprised primarily of Organon, a human health business, and Intervet, an animal health business. It also includes Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit of Organon.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Press release dated November 19, 2007 titled "Schering-Plough Completes Acquisition of Organon BioSciences"

---

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/ Steven H. Koehler  
Steven H. Koehler  
Vice President and Controller

Date: November 26, 2007

---

**Table of Contents**

Exhibit Index

Exhibit

Number      Description

99.1          Press release dated November 19, 2007 titled Schering-Plough Completes Acquisition of Organon  
BioSciences